Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

医学 贝伐单抗 中期分析 临床终点 肾细胞癌 内科学 α-干扰素 肿瘤科 安慰剂 α-干扰素 意向治疗分析 外科 胃肠病学 随机对照试验 干扰素 化疗 免疫学 病理 替代医学
作者
Bernard J. Escudier,Anna Pluzanska,P. Koralewski,Alain Ravaud,Sergio Bracarda A,Cezary A. Szczylik,Christine Chevreau,Marek Filipek,Bohuslav Melichar,Emilio Bajetta,В. А. Горбунова,Jacques‐Olivier Bay,I. Bodrogi,Agnieszka Jagiełło-Gruszfeld,N. Moore
出处
期刊:The Lancet [Elsevier BV]
卷期号:370 (9605): 2103-2111 被引量:2247
标识
DOI:10.1016/s0140-6736(07)61904-7
摘要

Vascular endothelial growth factor (VEGF) inhibition is a valid therapeutic approach in renal cell carcinoma. Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa was warranted.In a multicentre, randomised, double-blind, phase III trial, 649 patients with previously untreated metastatic renal cell carcinoma were randomised to receive interferon alfa-2a (9 MIU subcutaneously three times weekly) and bevacizumab (10 mg/kg every 2 weeks; n=327) or placebo and interferon alfa-2a (n=322). The primary endpoint was overall survival. Secondary endpoints included progression-free survival and safety. An interim analysis of overall survival was prespecified after 250 deaths. On the basis of new second-line therapies that became available while the trial was in progress, which could have confounded analyses of overall survival data, we agreed with regulatory agencies that the pre-planned final analysis of progression-free survival would be acceptable for regulatory submission. The protocol was amended to allow the study to be unblinded at this point. The final analysis of progression-free survival is reported here. Efficacy analyses were done by intention to treat. This trial is registered with centerwatch.com, number BO17705E.325 patients in the bevacizumab plus interferon alfa group and 316 in the placebo plus interferon alfa group received at least one dose of study treatment. At the time of unblinding, 230 progression events had occurred in the bevacizumab plus interferon alfa group and 275 in the control group; there were 114 deaths in the bevacizumab plus interferon alfa group and 137 in the control group. Median duration of progression-free survival was significantly longer in the bevacizumab plus interferon alfa group than it was in the control group (10.2 months vs 5.4 months; HR 0.63, 95% CI 0.52-0.75; p=0.0001). Increases in progression-free survival were seen with bevacizumab plus interferon alfa irrespective of risk group or whether reduced-dose interferon alfa was received. Deaths due to adverse events were reported in eight (2%) patients who received one or more doses of bevacizumab and seven (2%) of those who did not receive the drug. Only three deaths in the bevacizumab arm were considered by investigators to be possibly related to bevacizumab. The most commonly reported grade 3 or worse adverse events were fatigue (40 [12%] patients in the bevacizumab group vs 25 [8%] in the control group) and asthenia (34 [10%] vs 20 [7%]).The combination of bevacizumab with interferon alfa as first-line treatment in patients with metastatic renal cell carcinoma results in a significant improvement in progression-free survival, compared with interferon alfa alone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
若若1223完成签到 ,获得积分10
2秒前
阳佟水蓉发布了新的文献求助10
2秒前
Nov2发布了新的文献求助10
2秒前
qiuxiu完成签到,获得积分10
2秒前
2秒前
sortie发布了新的文献求助30
4秒前
循环bug完成签到,获得积分10
4秒前
情怀的应助被OSBORN采纳,获得30
5秒前
5秒前
5秒前
5秒前
Glacier完成签到 ,获得积分10
6秒前
6秒前
司空威完成签到,获得积分10
7秒前
7秒前
单纯的初晴完成签到,获得积分10
7秒前
7秒前
8秒前
过来抱抱发布了新的文献求助10
8秒前
9秒前
9秒前
11秒前
bigbigpig发布了新的文献求助10
12秒前
zjy发布了新的文献求助10
12秒前
李魏发布了新的文献求助10
12秒前
fn3340完成签到,获得积分10
12秒前
Lucas的应助被科研通管家采纳,获得10
13秒前
彭于晏的应助被科研通管家采纳,获得10
13秒前
orixero的应助被科研通管家采纳,获得10
13秒前
科研通AI2S的应助被科研通管家采纳,获得10
13秒前
13秒前
我是老大的应助被周迅采纳,获得10
14秒前
英俊的铭的应助被科研通管家采纳,获得10
14秒前
秋风的应助被科研通管家采纳,获得20
14秒前
FashionBoy的应助被科研通管家采纳,获得10
14秒前
李爱国的应助被科研通管家采纳,获得10
14秒前
Singularity的应助被科研通管家采纳,获得10
14秒前
14秒前
英俊的铭的应助被科研通管家采纳,获得100
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170973
求助须知:如何正确求助?哪些是违规求助? 9563727
关于积分的说明 21771951
捐赠科研通 7762452
什么是DOI,文献DOI怎么找? 3430786
关于科研通互助平台的介绍 2554629
邀请新用户注册赠送积分活动 2475637